CG Oncology, which develops treatments for bladder cancer, is receiving analyst attention regarding its potential benefits from Trump-era tariffs and the broader upside in AI stocks.
2 reports, 1 independent
Updated Aug 20
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CG Oncology, which develops treatments for bladder cancer, is receiving analyst attention regarding its potential benefits from Trump-era tariffs and the broader upside in AI stocks.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- CG Oncology, Inc. is developing targeted oncolytic virus therapy for high-risk non-muscle invasive bladder cancer.Sub-event
Analyst firms reiterated Buy ratings on CG Oncology, noting the potential upside for AI stocks benefiting from market trends.1 source
- Morgan Stanley raised price target on CG Oncology, linking it to tariff benefits for AI stocks.
Keep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- AI stocks are benefiting from Trump-era tariffs, and Brian Schwartz maintained an Outperform rating on Workday on September 5th.
- Goldman Sachs and Zeta Interactive noted that tariffs and onshoring benefit AI stocks, citing accelerated Q2 growth and raising price targets.
- Trump tariffs and onshoring benefit AI stocks, leading to automation and robotics support agreements involving Amazon and Richtech Robotics.
Coverage
Newest first; wire copies grouped- Insider MonkeyH.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT CG Oncology, Inc. (NASDAQ:CGON) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 11, Andres Y. Maldonado fro
- Unknown outlet